Pharmaceutical formulations
First Claim
Patent Images
1. A Cannabis-based pharmaceutical formulation “
- for use in administration via a mucosal surface”
which comprises both the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC), or the cannabinoids tetrahydrocannabinovarin (THCV) and cannabidivarin (CBDV), wherein the formulation is in a liquid dosage form producing particles having a mean aerodynamic particle size between 15 and 45 microns.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention relates to pharmaceutical formulations for use in the administration of lipophilic medicaments via mucosal surfaces. In particular the invention provides pharmaceutical formulations for use in administration of a lipophilic medicament via a mucosal surface which upon hydration form an emulsion containing the lipophilic medicament which is capable of adhering to a mucosal surface and allowing controlled release of the medicament. The invention further provides pharmaceutical formulations which contain, as active ingredients, specific combinations of cannabinoids in pre-defined ratios.
-
Citations
38 Claims
-
1. A Cannabis-based pharmaceutical formulation “
- for use in administration via a mucosal surface”
which comprises both the cannabinoids cannabidiol (CBD) and tetrahydrocannabinol (THC), or the cannabinoids tetrahydrocannabinovarin (THCV) and cannabidivarin (CBDV), wherein the formulation is in a liquid dosage form producing particles having a mean aerodynamic particle size between 15 and 45 microns. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 37, 38)
- for use in administration via a mucosal surface”
-
17. A method of preparing a Cannabis-based pharmaceutical formulation which comprises CBD and THC or CBDV and THCV which method comprises the steps of:
-
a) providing at least one dried Cannabis plant containing CBD and THC or CBDV and THCV;
b) preparing an extract of said at least one Cannabis plant;
c) formulating a material from said extract or extracts prepared in step (b) d) further formulating the product of step (c) into a pharmaceutical formulation in a liquid dosage form producing particles having a mean aerodynamic particle size between 15 and 45 microns. - View Dependent Claims (18, 19, 20, 21, 36)
-
Specification